A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety: Serious Adverse Events (SAEs) and new chronic diseases
Timeframe: 5 years from randomization
Overall survival
Timeframe: 5 years from randomization
Relapse of oropharyngeal cancer
Timeframe: 5 years from randomization
New malignancies
Timeframe: 5 years from randomization
Zoonotic Diseases
Timeframe: 5 years from randomization